{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:18:35Z","timestamp":1787635115772,"version":"build-2736575974"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Natural killer cell alloreactivity contributes to the graft-versus-leukemia (GVL) effect of haploidentical hematopoietic stem cell transplantation (haplo-HSCT). However, its importance remains controversial across studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective analysis, we studied NK cell alloreactivity and its association with clinical outcomes using the education model in patients with hematologic malignancies undergoing transplantation. Patients were stratified by the presence or absence of alloreactivity assessment, which was defined by the coexistence (in the donor) of four germline-encoded inhibitory killer cell immunoglobulin-like receptors (iKIRs) and their corresponding self-human leukocyte antigen (HLA)-I ligands.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In a cohort of 1,209 patients,793 individuals (65.6%) had no loss of iKIR ligands, while 416 cases showed alloreactivity characterized by the absence of at least one ligand. Among the missing single ligand, the absence of HLA-A3\/A11 epitope was the most prevalent (28.4%), followed by Bw4 (25.2%), C2 (23.6%), and C1 (10.6%). Only patients with KIR3DL2-A3\/A11-mediated alloreactivity exhibited a substantially reduced 3-year cumulative incidence of relapse (CIR) compared to those without this predicted alloreactivity (16.2%; 95% confidence interval [CI], 10.1-23.5%; and 30.1%; 95% CI, 27.1-33.3%;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.0006). Multivariate analysis confirmed A3\/A11 deficiency as an independent protective factor against relapse (adjusted hazard ratio 0.487; 95% CI, 0.300-0.790;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.0035). Moreover, alternative predictive models failed to reliably forecast relapse risk.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Our result suggest that NK cell alloreactivity driven by the absence of HLA-A3\/A11 may enhance NK cell-mediated surveillance against leukemia cells; therefore, incorporating KIR3DL2-A3\/A11 compatibility assessment can refine donor selection strategies aimed at reducing relapse incidence in patients undergoing haplo-HSCT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1907346","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T04:22:45Z","timestamp":1787631765000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Contrasting relapse rate associated with the absence of HLA-A3\/A11 in T cell-replete haploidentical transplantation"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiang-Feng","family":"Tang","sequence":"first","affiliation":[{"name":"National Engineering Laboratory for Birth Defects Prevention and Control of Key Technology, Beijing Key Laboratory of Pediatric Organ Failure, Department of Pediatrics, The Seventh Medical Center of PLA General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Fei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Beijing BFR Gene Diagnostics","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Jie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Aerospace Center Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Hui","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Beijing Children\u2019s Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Qi","family":"Wang","sequence":"additional","affiliation":[{"name":"Medical Centre of Haematology, Xinqiao Hospital of Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-Yu","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplant, Hebei Yanda Lu Daopei Hospital","place":["Langfang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Dong","family":"Wang","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation Center, Shanghai Children\u2019s Medical Center, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Beijing Children\u2019s Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Mei","family":"Feng","sequence":"additional","affiliation":[{"name":"Medical Centre of Haematology, Xinqiao Hospital of Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Hua","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Beijing Children\u2019s Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Guang","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Beijing Children\u2019s Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Jian","family":"Si","sequence":"additional","affiliation":[{"name":"National Engineering Laboratory for Birth Defects Prevention and Control of Key Technology, Beijing Key Laboratory of Pediatric Organ Failure, Department of Pediatrics, The Seventh Medical Center of PLA General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lu","sequence":"additional","affiliation":[{"name":"National Engineering Laboratory for Birth Defects Prevention and Control of Key Technology, Beijing Key Laboratory of Pediatric Organ Failure, Department of Pediatrics, The Seventh Medical Center of PLA General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao-Quan","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Beijing Children\u2019s Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Jun","family":"Liu","sequence":"additional","affiliation":[{"name":"Beijing BFR Gene Diagnostics","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Bo","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Aerospace Center Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-846824","article-title":"Mechanisms of immune escape after allogeneic hematopoietic cell transplantation","volume":"133","author":"Zeiser","year":"2019","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/tan.70340","article-title":"NK alloreactivity evaluation according to KIR-HLA interaction models influences the outcome of haploidentical haematopoietic stem-cell transplantation based on post-transplant cyclophosphamide","volume":"106","author":"Ni\u00f1o-Ram\u00edrez","year":"2025","journal-title":"HLA"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-103325","article-title":"Temporal, quantitative, and functional characteristics of single-KIR-positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation","volume":"112","author":"Vago","year":"2008","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bict.2026.100038","article-title":"Disarming the natural killers: mechanisms of NK cell dysfunction in hematological malignancies","volume":"2","author":"Takanlu","year":"2026","journal-title":"Blood Immunol Cell Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-752170","article-title":"Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation","volume":"131","author":"Cooley","year":"2018","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01259-0","article-title":"Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: a study on behalf of the CTIWP of the EBMT","volume":"56","author":"Ruggeri","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1350470","article-title":"Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight","volume":"15","author":"Schetelig","year":"2024","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0170-5","article-title":"Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide","volume":"33","author":"Shimoni","year":"2019","journal-title":"Leukemia"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1801489","article-title":"Impact of KIR\/HLA incompatibilities on NK cell reconstitution and clinical outcome after T cell-replete haploidentical hematopoietic stem cell transplantation with posttransplant cyclophosphamide","volume":"202","author":"Willem","year":"2019","journal-title":"J Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.11.022","article-title":"Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation","volume":"16","author":"Symons","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1033871","article-title":"Donor selection for KIR alloreactivity is associated with superior survival in haploidentical transplant with PTCy","volume":"13","author":"Zou","year":"2022","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404566","article-title":"Deleterious effects of KIR ligand incompatibility on clinical outcomes in haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion","volume":"21","author":"Huang","year":"2007","journal-title":"Leukemia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-4113","article-title":"NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect","volume":"105","author":"Nguyen","year":"2005","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704900","article-title":"Haplotype mismatched transplantation using high doses of peripheral blood CD34+ cells together with stratified conditioning regimens for high-risk adult acute myeloid leukemia patients: a pilot study in a single Korean institution","volume":"35","author":"Kim","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002887","article-title":"External validation of models for KIR2DS1\/KIR3DL1-informed selection of hematopoietic cell donors fails","volume":"135","author":"Schetelig","year":"2020","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.584520","article-title":"Haplotype motif-based models for KIR-genotype informed selection of hematopoietic cell donors fail to predict outcome of patients with myelodysplastic syndromes or secondary acute myeloid leukemia","volume":"11","author":"Schetelig","year":"2021","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.10.008","article-title":"The broad spectrum of human natural killer cell diversity","volume":"47","author":"Freud","year":"2017","journal-title":"Immunity"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nri2835","article-title":"Current perspectives of natural killer cell education by MHC class I molecules","volume":"10","author":"H\u00f6glund","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.70.7059","article-title":"KIR3DL1\/HLA-B subtypes govern acute myelogenous leukemia relapse after hematopoietic cell transplantation","volume":"35","author":"Boudreau","year":"2017","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.07.005","article-title":"Cell-extrinsic MHC class I molecule engagement augments human NK cell education programmed by cell-intrinsic MHC class I","volume":"45","author":"Boudreau","year":"2016","journal-title":"Immunity"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1028162","article-title":"Comparison of NK alloreactivity prediction models based on KIR-MHC interactions in haematopoietic stem cell transplantation","volume":"14","author":"Dhuyser","year":"2023","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1643244","article-title":"Prediction and effect on relapse of natural killer cell alloreactivity based on KIR-HLA interactions in pediatric haploidentical transplantation with anti-thymoglobulin","volume":"16","author":"Tang","year":"2025","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705445","article-title":"Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies","volume":"38","author":"Huang","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.10.032","article-title":"HLA-haploidentical stem cell transplantation for hematologic malignancies","volume":"16","author":"Fuchs","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.13539","article-title":"Effect of the in vivo application of granulocyte colony-stimulating factor on NK cells in bone marrow and peripheral blood","volume":"22","author":"Yu","year":"2018","journal-title":"J Cell Mol Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.9.6010","article-title":"Estimation of the size of the alloreactive NK cell repertoire: studies in individuals homozygous for the group A KIR haplotype1","volume":"181","author":"Fauriat","year":"2008","journal-title":"J Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100570","article-title":"Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment","volume":"207","author":"Joncker","year":"2010","journal-title":"J Exp Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100986","article-title":"MHC class I-deficient natural killer cells acquire a licensed phenotype after transfer into an MHC class I-sufficient environment","volume":"207","author":"Elliott","year":"2010","journal-title":"J Exp Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.05.020","article-title":"Conflicting impact of alloreactive NK cells on transplantation outcomes after haploidentical transplantation: do the reconstitution kinetics of natural killer cells create these differences","volume":"17","author":"Zhao","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1182\/bloodadvances.2022008514","article-title":"Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia","volume":"7","author":"Heidenreich","year":"2023","journal-title":"Blood Adv"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01646","article-title":"Natural killer cells offer differential protection from leukemia in Chinese Southern Han","volume":"10","author":"Deng","year":"2019","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/molbev\/msab053","article-title":"Adaptive admixture of HLA class I allotypes enhanced genetically determined strength of natural killer cells in East Asians","volume":"38","author":"Deng","year":"2021","journal-title":"Mol Biol Evol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.640334","article-title":"High-resolution analysis identifies high frequency of KIR-A haplotypes and inhibitory interactions of KIR with HLA class I in Zhejiang Han","volume":"12","author":"Tao","year":"2021","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1907346\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T04:22:46Z","timestamp":1787631766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1907346\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2026.1907346"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1907346","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"article-number":"1907346"}}